Novavax (Novavax) Cash per Share

: $4.08 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Novavax's Cash per Share for the quarter that ended in Dec. 2023 was $4.08.

Novavax Cash per Share Historical Data

The historical data trend for Novavax's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

2.44

10.02

19.98

15.54

4.08

Novavax Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash per Share																15.54	7.24	5.36	5.48	4.08

Novavax Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Novavax's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	568.505	/	139.5
	=	4.08

Novavax's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	568.505	/	139.5
	=	4.08

Novavax (NAS:NVAX) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Novavax Cash per Share Related Terms

Thank you for viewing the detailed overview of Novavax's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax (Novavax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

NVAX:Mexico NVV1:Germany

Address

21 Firstfield Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Executives

Filip Dubovsky	officer: President, R&D	C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn	officer: President, R&D	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara	officer: EVP, Chief Strategy Officer	333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs	director, officer: President and CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers	director	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
James F Young	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Herrmann John A Iii	officer: SVP, General Counsel	C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck	director, officer: President and CEO	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino	officer: SVP, CBO and CFO	9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly	officer: EVP, CFO and Treasurer	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans	director	1048 TEXAN TRAIL, GRAPEVINE TX 76051
Rachel K. King	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Mcmanus Michael A Jr	director	241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn	director	C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100